RxDoctor Payments Data

Vera Prisacari, MD

Psychiatry · Modesto, CANPI 1982196564

Payments from drug & device makers

$2,174in general payments, 2019–2025

Across 73 payments — averaging $29.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$339
  • Axsome Therapeutics, Inc.$305
  • AbbVie$262
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$223
  • Teva Pharmaceuticals USA, Inc.$150
  • Johnson & Johnson$139
  • plus $757 from 11 others

What the payments were for

  • Food & beverage$2,174100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,174 in reported general payments places this provider in the 80th percentile of 4,954 psychiatry providers in California.

See all psychiatry providers in California

Medicare billing

Part B allowed, 2024
$91,391
Medicare patients
159
Services billed
855

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CaplytaLumateperone Tosylate13$39,943
Abilify MaintenaAripiprazole13$28,375
TrintellixVortioxetine Hydrobromide12$9,702
Aripiprazole69$6,394
Paliperidone ErPaliperidone12$4,622
Lurasidone Hcl32$4,442
Duloxetine Hcl112$4,316
Quetiapine Fumarate134$3,724
Desvenlafaxine Succinate ErDesvenlafaxine Succinate36$3,203
Haloperidol45$2,224
Trazodone Hcl135$2,100
Bupropion XlBupropion Hcl50$1,962
Divalproex Sodium ErDivalproex Sodium12$1,960
Olanzapine72$1,944
Buspirone Hcl122$1,901

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$223$39,94313 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena$55$28,37513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,954 psychiatry providers in California.

Other psychiatry in Modesto

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →